Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

12.1%

15 terminated/withdrawn out of 124 trials

Success Rate

77.3%

-9.2% vs industry average

Late-Stage Pipeline

23%

28 trials in Phase 3/4

Results Transparency

76%

39 of 51 completed trials have results

Key Signals

19 recruiting39 with results11 terminated4 withdrawn

Enrollment Performance

Analytics

Phase 2

38(45.8%)

Phase 3

28(33.7%)

N/A

14(16.9%)

Phase 1

3(3.6%)

83Total

Phase 2(38)

Phase 3(28)

N/A(14)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (124)

Showing 20 of 124 trials

NCT06592924Phase 3Recruiting

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Role: collaborator

NCT06686771Phase 3Recruiting

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Role: collaborator

NCT06205485Phase 3Recruiting

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

Role: collaborator

NCT03419234Phase 2Active Not Recruiting

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

Role: lead

NCT01806129Not ApplicableActive Not Recruiting

Reproductive Health Program in Patients With Cancer

Role: lead

NCT04438382Phase 2Terminated

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Role: lead

NCT05863195Phase 3Recruiting

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Role: lead

NCT04527549Phase 2Terminated

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Role: lead

NCT02445391Phase 3Active Not Recruiting

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Role: lead

NCT03253848Not ApplicableActive Not Recruiting

Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia

Role: lead

NCT04221438Phase 2Terminated

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Role: lead

NCT03504644Phase 1Active Not Recruiting

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Role: lead

NCT04239573Recruiting

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

Role: lead

NCT04031677Phase 3Recruiting

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

Role: collaborator

NCT07001748Phase 2Recruiting

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Role: lead

NCT06295367Not ApplicableRecruiting

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

Role: lead

NCT06112613Not ApplicableRecruiting

Mobile Health for Adherence in Breast Cancer Patients

Role: lead

NCT02734537Phase 2Recruiting

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Role: lead

NCT06475989Phase 3Recruiting

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Role: lead

NCT04423211Phase 3Recruiting

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Role: lead